Gastrointestinal and hepatic disorders
We observed four cases of GI and hepatic disorders, in particular
“nausea”, “vomiting”, “diarrhoea” and “hypertransaminasemia”. In
these cases, all classes of COVID-19 medications were involved and GI
intolerance often led to pharmacological switching between the
associations lopinavir/ritonavir and darunavir/cobicistat. This kind of
non-specific ADRs is frequently (common or very common )
observed for all medication classes, including that of COVID-19
treatments [30,
36-38,
52]. The evaluation of
causality assessment for GI and hepatic disorders must take into
consideration the presence of concomitant medications and the underlying
SARS-CoV-2 infection, which is commonly associated with GI symptoms
[53].